i-Base home
Search Menu
  • Home
  • HTB
  • 2002
  • May

HTB

May 2002

Contents

Antiretrovirals

  • Hydroxyurea: in vitro evidence of potency against HIV viral reservoirs
  • Transient increases in viral load are common among people on HAART, finds a study of UK patients
  • Meta-analysis supports triple therapy for HIV infection

Pregnancy

  • Reduction of mother to child HIV-1 transmission: breastfeeding negates benefits of short course regimens
  • Nevirapine at the centre of MTCT controversy
  • Mothers, orphans, and prevention of paediatric AIDS

Side effects

  • Altered adipocyte differentiation associated with protease inhibitors and lipoatrophy
  • High mortality rate in patients with severe NRTI-associated lactic acidosis
  • Tenofovir adversely affects development in foetal monkeys
  • Tenofovir not toxic to mitochondria in human cell culture

OIs, coinfections and complications

  • HIV infection is a risk factor for external genital warts, study suggests
  • American study finds KS-associated herpesvirus is highly prevalent among gay men

Other news

  • Gilead made misleading and illegal statements about Viread, says FDA
  • Barcelona conference organisers issue nine-point plan of action on global emergency

On the web

  • Incorporating antiretroviral resistance testing into clinical practice
  • Management of co-infection with HIV and TB

PDFs

  • Volume 3 Number 4 May 2002 PDF
  • HTB RSS

Early access

  • Single undetectable viral load is sufficient for U=U in the context of good adherence 23 January 2021
  • US FDA approves long-acting injectable HIV treatment: monthly dosing 22 January 2021
  • Latest update on HIV and COVID-19 from BHIVA and EACS (January 2021) 15 January 2021
  • Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study       14 January 2021
  • All early access reports

Current issues

  • January 2021
  • December 2020
  • November 2020
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook